Reuters logo
BRIEF-Ablynx lowers net cash burn guidance for the full year 2017
August 24, 2017 / 5:24 AM / a month ago

BRIEF-Ablynx lowers net cash burn guidance for the full year 2017

Aug 24 (Reuters) - ABLYNX NV:

* ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE

* H1 REVENUES OF €34.7 MILLION (2016: €53.1 MILLION)

* H1 OPERATING LOSS OF €24.8 MILLION (2016: €2.0 MILLION)

* H1 NET CASH BURN OF €30.9 MILLION (2016: €19.0 MILLION)

* H1 CASH POSITION OF €204.5 MILLION (2016: €288.7 MILLION)

* ON TRACK TO REPORT TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB IN PATIENTS WITH ATTP IN LATE Q3 2017

* EXPECTS TO REPORT RESULTS OF ONGOING SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS BEFORE END OF YEAR

* IN Q4 2017, CO PLANS TO FILE FOR REGULATORY APPROVAL TO ENABLE A PHASE II STUDY IN JAPAN WITH ALX-0171 IN INFANTS HOSPITALISED WITH A RSV INFECTION

* COMPANY IS LOWERING ITS NET CASH BURN GUIDANCE FOR THE FULL YEAR 2017 AND IT IS NOW EXPECTED TO BE IN THE RANGE OF €65-75 MILLION

* IN Q4 2017, WILL ALSO FILE FOR REGULATORY APPROVALS TO ENABLE GLOBAL PHASE II STUDY WITH ALX-0171 IN ADULTS WHO UNDERWENT STEM CELL TRANSPLANTATION AND BECAME INFECTED WITH RSV Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below